Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.

Abstract: A process for preparing a compound of Formula (1a): or a pharmaceutically acceptable salt thereof.

Abstract: Provided are a compound that is useful for the prevention of and/or as a treatment agent for a disease in which a group II mGlu receptor is involved; and a medical application of said compound. Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.

Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.

Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.

Abstract: Provided are a compound that is useful for the prevention of and/or as a treatment agent for a disease in which a group II mGlu receptor is involved; and a medical application of said compound. Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Provided are a compound that is useful for the prevention of and/or as a treatment agent for a disease in which a group II mGlu receptor is involved; and a medical application of said compound. Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Provided are a compound that is useful for the prevention of and/or as a treatment agent for a disease in which a group II mGlu receptor is involved; and a medical application of said compound. Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.

Abstract: A content administration system receives user identification information from a terminal device via the Internet. The content administration system then specifies content administration information storage means corresponding to the received user identification information. The content administration system acquires object path information correlated to sharing permission information from a content administration information storage means of another unspecified user. The content administration system then acquires an icon image from the icon image storage means. The content administration system then makes display control information for the content administration screen containing the icon leading to the object based on the acquired icon image and the acquired object path information. The content administration system transmits the made display control information to the terminal device via the Internet.

Abstract: A content administration system receives user identification information from a terminal device via the Internet. The content administration system then specifies content administration information storage means corresponding to the received user identification information. The content administration system acquires object path information correlated to sharing permission information from a content administration information storage means of another unspecified user. The content administration system then acquires an icon image from the icon image storage means. The content administration system then makes display control information for the content administration screen containing the icon leading to the object based on the acquired icon image and the acquired object path information. The content administration system transmits the made display control information to the terminal device via the Internet.

Abstract: A content administration system receives user identification information from a terminal device via the Internet. The content administration system then specifies content administration information storage means corresponding to the received user identification information. The content administration system acquires object path information correlated to sharing permission information from a content administration information storage means of another unspecified user. The content administration system then acquires an icon image from the icon image storage means. The content administration system then makes display control information for the content administration screen containing the icon leading to the object based on the acquired icon image and the acquired object path information. The content administration system transmits the made display control information to the terminal device via the Internet.

Abstract: A content administration system receives user identification information from a terminal device via the Internet. The content administration system then specifies content administration information storage means corresponding to the received user identification information. The content administration system acquires object path information correlated to sharing permission information from a content administration information storage means of another unspecified user. The content administration system then acquires an icon image from the icon image storage means. The content administration system then makes display control information for the content administration screen containing the icon leading to the object based on the acquired icon image and the acquired object path information. The content administration system transmits the made display control information to the terminal device via the Internet.

Abstract: A content administration system receives user identification information from a terminal device via the Internet. The content administration system then specifies content administration information storage means corresponding to the received user identification information. The content administration system acquires object path information correlated to sharing permission information from a content administration information storage means of another unspecified user. The content administration system then acquires an icon image from the icon image storage means. The content administration system then makes display control information for the content administration screen containing the icon leading to the object based on the acquired icon image and the acquired object path information. The content administration system transmits the made display control information to the terminal device via the Internet.

Abstract: A drug having a high affinity for benzodiazepine ?3 receptors and showing curative and preventive effects for anxiety and depression, which comprises as the active ingredient, for example, a compound of the formula (1): wherein R1 and R2 are independently a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group, etc., R3 and R4 are independently a hydrogen atom, an optionally substituted alkyl group, etc., R5, R6, R7 and R8 are independently a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group, etc., X is an oxygen atom, a sulfur atom, NR10, etc. (in which R10 is a hydrogen atom, an optionally substituted alkyl group, etc.

Abstract: There is provided a selective serotonin reuptake inhibitor having affinity for serotonin 1A receptors which comprises a cyclic amine represented by the formula: wherein G represents a formula (2): a prodrug of said cyclic amine, or a pharmaceutically acceptable salt of said cyclic amine or prodrug, as an active ingredient.

Abstract: A content administration system receives user identification information from a terminal device via the Internet. The content administration system then specifies content administration information storage means corresponding to the received user identification information. The content administration system acquires object path information correlated to sharing permission information from a content administration information storage means of another unspecified user. The content administration system then acquires an icon image from the icon image storage means. The content administration system then makes display control information for the content administration screen containing the icon leading to the object based on the acquired icon image and the acquired object path information. The content administration system transmits the made display control information to the terminal device via the Internet.

Abstract: A serotonin reuptake inhibitor containing a cyclic amine represented by the following formula, a prodrug thereof, or a pharmaceutically acceptable salt of said cyclic amine or prodrug as an active ingredient: wherein R0 is a hydrogen atom, a halogen atom, an alkyl group, a substituted alkyl group, a hydroxyl group, an alkoxy group or the like, R3 is a hydrogen atom or the like, Y is an alkylene group or the like, Z is a hydrogen atom, a cycloalkyl group, an aryl group or the like, n is 1, 2 or 3, and m is 2, 3, 4, 5 or 6.

Abstract: A serotonin reuptake inhibitor containing a cyclic amine represented by the following formula, a prodrug thereof, or a pharmaceutically acceptable salt of said cyclic amine or prodrug as an active ingredient: 1